Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 1, 2007, Pages 190-195

  Parkinson, Craig ^a,e   Burman, Pia ^b   Messig, Michael ^c   Trainer, Peter J ^d  

^a IPSWICH HOSPITAL   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c PFIZER INC   (United States)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; DEMOGRAPHY; DISEASE ACTIVITY; ESTROGEN THERAPY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 33846040409     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1412     Document Type: Article

References (39)

1. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
2. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
3. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long-term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 358:1754-1759
4. Ho KY, Evans WS, Blizzard RM, Veldhuis JD, Merriam GR, Samojlik E, Furlanetto R, Rogol AD, Kaiser DL, Thorner MO 1987 Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 64:51-58
5. van den Berg G, Veldhuis JD, Frolich M, Roelfsema F 1996 An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 81:2460-2467
6. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lundberg PA, Bengtsson BA 1994 Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 41:351-357
7. Juul A, Bang P, Hertel NT, Main K, Dalgaard P, Jorgensen K, Muller J, Hall K, Skakkebaek NE 1994 Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 78:744-752
8. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82:550-555
9. Johansson AG, Engstrom BE, Ljunghall S, Karlsson FA, Burman P 1999 Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 84:2002-2007
10. Janssen YJ, Frolich M, Roelfsema F 1997 A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 82:129-135
11. Janssen YJ, Helmerhorst F, Frolich M, Roelfsema F 2000 A switch from oral (2 mg/day) to transdermal (50 μg/day) 17β-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency. J Clin Endocrinol Metab 85:464-467
12. Cook DM, Ludlam WH, Cook MB 1999 Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 84:3956-3960
13. Eden Engstrom B, Burman P, Johansson AG, Wide L, Karlsson FA 2000 Effects of short-term administration of growth hormone in healthy young men, women, and women taking oral contraceptives. J Intern Med 247:570-578
14. Parkinson C, Ryder WDJ, Trainer PJ 2001 The relationship between serum GH and serum IGF-I in acromegaly is gender specific. J Clin Endocrinol Metab 86:5240-5244
15. Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ 2002 Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 57:59-64
16. Lieberman SA, Mitchell AM, Marcus R, Hintz RL, Hoffman AR 1994 The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 26:229-233
17. Arvat E, Ceda G, Ramunni J, Lanfranco F, Aimaretti G, Gianotti L, Broglio F, Ghigo E 1998 The IGF-I response to very low rhGH doses is preserved in human ageing. Clin Endocrinol (Oxf) 49:757-763
18. Peacey SR, Toogood AA, Veldhuis JD, Thorner MO, Shalet SM 2001 The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy. J Clin Endocrinol Metab 86:259-266
19. Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F 2005 Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients. Clin Endocrinol (Oxf) 63:294-297
20. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF 1999 Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84:2098-2103
21. Demaris A 2004 Regression with social data: modeling continuous and limited response variables. New York: John Wiley, Sons
22. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE 1979 Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138-1142
23. Holdaway IM, Rajasoorya RC, Gamble GD 2004 Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
24. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP 1998 Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 83:3913-3919
25. Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G, Lombardi G 2002 Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 25:532-538
26. Eden Engstrom B, Burman P, Karlsson FA 2002 Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 56:73-77
27. Ross RJ, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KK 2001 Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
28. Feelders RA, Bidlingmaier M, Strasburger CJ, Janssen JA, Uitterlinden P, Hofland LJ, Lamberts SW, van der Lely AJ, de Herder WW 2005 Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 90:6480-6489
29. Hattori N, Kurahachi H, Ikekubo K, Ishihara T, Moridera K, Hino M, Saiki Y, Imura H 1991 Effects of sex and age on serum GH binding protein levels in normal adults. Clin Endocrinol (Oxf) 35:295-297
30. Bulow B, Ahren B, Fisker S, Dehlin O, Hagberg B, Jensen E, Svensson T, Samuelsson G, Erfurth EM 2003 The gender differences in growth hormone-binding protein and leptin persist in 80-year-old men and women and is not caused by sex hormones. Clin Endocrinol (Oxf) 59:482-486
31. Peacey SR, Toogood AA, Shalet SM 1998 Hypothalamic dysfunction in "cured" acromegaly is treatment modality dependent. J Clin Endocrinol Metab 83:1682-1686
32. Darzy KH, Pezzoli SS, Thorner MO, Shalet SM 2005 The dynamics of growth hormone (GH) secretion in adult cancer survivors with severe GH deficiency acquired after brain irradiation in childhood for nonpituitary brain tumors: evidence for preserved pulsatility and diurnal variation with increased secretory disorderliness. J Clin Endocrinol Metab 90:2794-2803
33. Peacey SR, Shalet SM 1999 Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary 2:63-69
34. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 82:3187-3191
35. Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G, Arosio M 2001 Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf) 55:183-189
36. Nanto-Salonen K, Muller HL, Hoffman AR, Vu TH, Rosenfeld RG 1993 Mechanisms of thyroid hormone action on the insulin-like growth factor system: all thyroid hormone effects are not growth hormone mediated. Endocrinology 132:781-788
37. Iglesias P, Bayon C, Mendez J, Gancedo PG, Grande C, Diez JJ 2001 Serum insulin-like growth factor type 1, insulin-like growth factor-binding protein-1, and insulin-like growth factor-binding protein-3 concentrations in patients with thyroid dysfunction. Thyroid 11:1043-1048
38. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G 2006 The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954-3961
39. Erfurth EM, Hagmar LE, Saaf M, Hall K 1996 Serum levels of insulin-like growth factor 1 and insulin-like growth factor-binding protein 1 correlate with serum free testosterone and sex hormone binding globulin levels in healthy young middle aged men. Clin Endocrinol (Oxf) 44:659-664